lapatinib has been researched along with vorinostat in 13 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (vorinostat) | Trials (vorinostat) | Recent Studies (post-2010) (vorinostat) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 2,529 | 181 | 1,840 |
| Protein | Taxonomy | lapatinib (IC50) | vorinostat (IC50) |
|---|---|---|---|
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Chain A, Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 0.95 | |
| Histone deacetylase 8 | Schistosoma mansoni | 1.3147 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Gli1 | Mus musculus (house mouse) | 2.23 | |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | 0.7472 | |
| cystic fibrosis transmembrane conductance regulator | Homo sapiens (human) | 1.55 | |
| Histone deacetylase 1 | Mus musculus (house mouse) | 0.1121 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.3382 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.2644 | |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | 0.0382 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.456 | |
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.5 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.5 | |
| Albumin | Homo sapiens (human) | 0.1072 | |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 4.66 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.0903 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.011 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.24 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.1582 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.053 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.116 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Leukotriene A-4 hydrolase | Mus musculus (house mouse) | 6.15 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.042 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.13 | |
| Delta-type opioid receptor | Homo sapiens (human) | 7.2 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 2.8 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 7.2 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.6096 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.086 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.322 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.1 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.2701 | |
| Histone deacetylase 1 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase | Rattus norvegicus (Norway rat) | 0.165 | |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | 0.07 | |
| Renin | Macaca fascicularis (crab-eating macaque) | 0.067 | |
| Histone deacetylase 3 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase-like amidohydrolase | Alcaligenaceae bacterium FB188 | 1 | |
| Histone deacetylase | Plasmodium falciparum 3D7 | 0.1 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.6115 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.3746 | |
| HD2 type histone deacetylase HDA106 | Zea mays | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.4211 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.5235 | |
| Carboxypeptidase B2 | Homo sapiens (human) | 0.362 | |
| Histone deacetylase 7 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 6 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 4 | Rattus norvegicus (Norway rat) | 0.165 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.9141 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2634 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5614 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.5926 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0945 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.0905 | |
| Histone deacetylase 6 | Mus musculus (house mouse) | 0.3742 | |
| Histone deacetylase | Zea mays | 0.029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, R; Cai, X; Forrester, J; Lai, CJ; Qian, C; Qu, H; Wang, J; Yin, L; Zhai, HX | 1 |
| Baer, T; Beckers, T; Ciossek, T; Eichhorn, E; Mahboobi, S; Maier, T; Pongratz, H; Sellmer, A; Winkler, M | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, S; Chen, YZ; Ding, C; Hu, G; Jiang, Y; Li, L; Tan, C; Zhang, C; Zhang, W | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Ajenjo, N; Albarrán, MI; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; Cuadrado-Urbano, M; García, AB; García-Serelde, B; Gómez de la Oliva, CA; Gómez-Casero, E; González Cantalapiedra, E; Hernández, AI; Klett, J; Martínez-González, S; Oyarzabal, J; Pastor, J; Rabal, O; Rodríguez-Arístegui, S; Varela, C | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Geng, P; Lin, F; Wang, S; Wu, C; Zhang, Q; Zhang, X; Zhou, Y; Zou, H | 1 |
3 review(s) available for lapatinib and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
10 other study(ies) available for lapatinib and vorinostat
| Article | Year |
|---|---|
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Enzyme Inhibitors; ErbB Receptors; Female; HeLa Cells; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Neoplasms; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2010 |
Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Topics: Acetylation; Acrylamides; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Histone Deacetylase Inhibitors; Histones; Humans; Isoenzymes; Lapatinib; Quinazolines; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Triazoles | 2017 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinolines; Structure-Activity Relationship; Triazoles | 2019 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Pharmacokinetic interaction study combining lapatinib with vorinostat in rats.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Hydroxamic Acids; Lapatinib; Male; Quinazolines; Rats, Sprague-Dawley; Vorinostat | 2015 |